SEC Form 4 · accession 0001551986-18-000017
INNOVATE BIOPHARMACEUTICALS, INC. · INNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
June Sherie Almenoff
Officer — COO and Chief Medical Officer
Period of report
Aug 24, 2018
Accepted (ET)
Aug 28, 2018 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551986
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Aug 24, 2018 | P | 100 | $4.85 | A | 100 | I | By Meadowlark Management LLC |
| Common stockF1 | Aug 24, 2018 | P | 400 | $4.99 | A | 500 | I | By Meadowlark Management LLC |
| Common stockF1 | Aug 27, 2018 | P | 47 | $4.90 | A | 547 | I | By Meadowlark Management LLC |
| Common stockF1 | Aug 27, 2018 | P | 253 | $4.96 | A | 800 | I | By Meadowlark Management LLC |
| Common stockF1 | Aug 27, 2018 | P | 100 | $4.94 | A | 900 | I | By Meadowlark Management LLC |
| Common stockF1 | Aug 24, 2018 | P | 500 | $4.85 | A | 1,400 | I | By Meadowlark Management LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.